As we all know that the Coronavirus is going to be a part of life and you need to learn with it. One need not panic and thus the pharma companies are going to benefit from it.
Jubilant Life Sciences has tied up with Gilead for Remdesivir which is an investigational anti-viral therapy developed by Gilead and it has received Emergency Use Authorisation (EUA) by USFDA to treat Covid-19. We feel that Jubilant Life Sciences tie-up with Gilead Will Pay handsome dividends
It is worth mentioning here that its subsidiary, Jubilant Generics Limited, has entered into a non-exclusive licensing agreement with Gilead Sciences that will grant Jubilant the right to register, manufacture and sell Gilead’s investigational drug remdesivir, a potential therapy for Covid-19 in 127 countries including India.
Jubilant will have the right to receive a technology transfer of the Gilead manufacturing process to scale up production to enable expedited access of the medicine to Covid-19 patients upon approvals by the regulatory authorities in respective countries.
Have a look at the stock chart which is on the verge of breakout and stock moving above 400 and sustaining above 445 will target the levels of 450,475,500,600 & can again reach its 26 week high which stands near 640 marks. The above news will act as a trigger to get the stock moving forward as the clarity emerges regarding the royalty payment.
Through these writeups, our aim is to awaken you from your deep slumber because "If you came from a middle-class family, it’s not your fault. However, if your kids come from a middle-class family, it is your fault."So, don't let them slog throughout life like you and instead develop another stream of income by utilising the useful tips for intraday trading and not to forget to maximise your profit potential using the Bank Nifty Intraday Option tips as we want each Indian to retire by age of 42 and start enjoying their life thereafter. Now is the time for you to act now !!
Jubilant Life Sciences has tied up with Gilead for Remdesivir which is an investigational anti-viral therapy developed by Gilead and it has received Emergency Use Authorisation (EUA) by USFDA to treat Covid-19. We feel that Jubilant Life Sciences tie-up with Gilead Will Pay handsome dividends
It is worth mentioning here that its subsidiary, Jubilant Generics Limited, has entered into a non-exclusive licensing agreement with Gilead Sciences that will grant Jubilant the right to register, manufacture and sell Gilead’s investigational drug remdesivir, a potential therapy for Covid-19 in 127 countries including India.
Jubilant will have the right to receive a technology transfer of the Gilead manufacturing process to scale up production to enable expedited access of the medicine to Covid-19 patients upon approvals by the regulatory authorities in respective countries.
Have a look at the stock chart which is on the verge of breakout and stock moving above 400 and sustaining above 445 will target the levels of 450,475,500,600 & can again reach its 26 week high which stands near 640 marks. The above news will act as a trigger to get the stock moving forward as the clarity emerges regarding the royalty payment.
Through these writeups, our aim is to awaken you from your deep slumber because "If you came from a middle-class family, it’s not your fault. However, if your kids come from a middle-class family, it is your fault."So, don't let them slog throughout life like you and instead develop another stream of income by utilising the useful tips for intraday trading and not to forget to maximise your profit potential using the Bank Nifty Intraday Option tips as we want each Indian to retire by age of 42 and start enjoying their life thereafter. Now is the time for you to act now !!
You
should Trade Less But Trade Accurately & this is Achieved with our Tip.
